Calando reports CALAA-01 data

Calando Pharmaceuticals Inc. (Pasadena, Calif.) said intracellularly localized CALAA-01 was dose-dependently detected inside tumor biopsies following systemic delivery of the siRNA in three metastatic melanoma patients. Calando said the open-label Phase I trial is thought to be the first demonstration in humans of "targeted siRNA-containing nanoparticle delivery to tumors using systemic administration, delivery of functional siRNAs and achievement of specific mRNA and protein reductions via RNAi." CALAA-01 is an siRNA duplex targeting the M2 subunit of ribonucleotide reductase (RRM2) delivered via the RONDEL delivery system. Data were published in Nature. ...